Prospective, randomized, double-blind clinical study of split-body comparison of topical hydroquinone and hexylresorcinol for skin pigment appearance.
Dyspigmentation
Facial
Hexylresorcinol
Hydroquinone
Melasma
Pigmentation
Topical
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
14
01
2021
accepted:
07
12
2022
revised:
24
11
2022
medline:
25
5
2023
pubmed:
12
12
2022
entrez:
11
12
2022
Statut:
ppublish
Résumé
Dyspigmentation is a common cosmetic concern in dermatology. Currently, the first line topical medication in the United States is hydroquinone. Hydroquinone use is associated with potential safety concerns including cytotoxicity to melanocytes, systemic absorption, metabolism in distant organs, and production of potentially carcinogenic metabolites. Hexylresorcinol is an ingredient that has been used in food preservation and as antiseptic has been shown to inhibit tyrosinase in vitro and has been studied as a novel skin-lightening agent. To perform a double-blind randomized split-body investigation of comparison on topical hexylresorcinol and hydroquinone on face and hands to assess for change in the appearance of skin tone and pigmentation. Thirty-two healthy female participants ages 35-65 (50.93 ± 7.37) years old with skin type I-IV were randomized to using either topical 1% hexylresorcinol or 2% hydroquinone on the left or right side of the face and corresponding hand over 12 weeks. The topical preparation was applied twice a day to assigned areas. Standardized photos were taken of the face and colorimetric measurements were taken of both sides of the forehead, cheeks and each hand at baseline (Day 0), week 4, and week 12. Of the 32 participants, 3 were lost to follow-up and the remaining were included in the final analysis. Pigmentation measured by colorimeter and clinical grading were significantly decreased at 4 and 12 weeks relative to baseline with no difference between the HR and HQ groups. No adverse effects were noted with either intervention. Hexylresorcinol 1% is well-tolerated and equivalent to hydroquinone 2% in reducing the appearance of facial and hand pigment. Further studies with an expanded population and longer time course are warranted.Registration No.: NCT04345094.
Identifiants
pubmed: 36502500
doi: 10.1007/s00403-022-02514-0
pii: 10.1007/s00403-022-02514-0
doi:
Substances chimiques
Hexylresorcinol
R9QTB5E82N
hydroquinone
XV74C1N1AE
Hydroquinones
0
Banques de données
ClinicalTrials.gov
['NCT04345094']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1207-1214Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Alam M, Havey J (2010) Photoaging. In: Draelos ZD (ed) In cosmetic dermatology. Wiley-Blackwell, Oxford, pp 13–21
doi: 10.1002/9781444317657.ch2
Raikar D, Javed MD, Takalkar AA (2020) A clinical and epidemiological study of hyperpigmentary disorder of face. Int J Res Dermatol 6:183–186. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20200207
doi: 10.18203/issn.2455-4529.IntJResDermatol20200207
Raveendra L, Sidappa H, Shree S (2020) A study of quality of life in patients with facial melanoses. Indian Dermatol Online J 11:154–157. https://doi.org/10.4103/idoj.IDOJ_209_19
doi: 10.4103/idoj.IDOJ_209_19
pubmed: 32477971
pmcid: 7247630
Vashi NA, Wirya SA, Inyang M, Kundu RV (2017) Facial hyperpigmentation in skin of color: special considerations and treatment. Am J Clin Dermatol 18:215–230. https://doi.org/10.1007/s40257-016-0239-8
doi: 10.1007/s40257-016-0239-8
pubmed: 27943085
Jimbow K, Obata H, Pathak MA, Fitzpatrick TB (1974) Mechanism of depigmentation by hydroquinone. J Invest Dermatol 62:436–449. https://doi.org/10.1111/1523-1747.ep12701679
doi: 10.1111/1523-1747.ep12701679
pubmed: 4206837
National Toxicology P (1989) NTP toxicology and carcinogenesis studies of hydroquinone (CAS No. 123-31-9) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 366:1–248
Wester RC, Melendres J, Hui X, Cox R, Serranzana S, Zhai H, Quan D, Maibach HI (1998) Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition. J Toxicol Environ Health A 54:301–317. https://doi.org/10.1080/009841098158863
doi: 10.1080/009841098158863
pubmed: 9638901
Westerhof W, Kooyers TJ (2005) Hydroquinone and its analogues in dermatology - a potential health risk. J Cosmet Dermatol 4:55–59. https://doi.org/10.1111/j.1473-2165.2005.40202.x
doi: 10.1111/j.1473-2165.2005.40202.x
pubmed: 17166200
Yin SN, Hayes RB, Linet MS, Li GL, Dosemeci M, Travis LB, Zhang ZN, Li DG, Chow WH, Wacholder S et al (1996) An expanded cohort study of cancer among benzene-exposed workers in China Benzene Study Group. Environ Health Perspect 104(Suppl 6):1339–1341. https://doi.org/10.1289/ehp.961041339
doi: 10.1289/ehp.961041339
pubmed: 9118917
pmcid: 1469739
National Center for Biotechnology Information. PubChem Compound Summary for CID 785, Hydroquinone. https://pubchem.ncbi.nlm.nih.gov/compound/Hydroquinone . Accessed 10 Dec 2022
Chaudhuri R (2015) Hexylresorcinol Providing Skin Benefits by Modulating Multiple Molecular Targets. In: Raja K Sivamani, Jared Jagdeo PE, Howard I Maibach (eds) Cosmeceuticals and Active Cosmetics, CRC Press, Boca Raton, pp 71–81.
Ross AB, Kamal-Eldin A, Aman P (2004) Dietary alkylresorcinols: absorption, bioactivities, and possible use as biomarkers of whole-grain wheat- and rye-rich foods. Nutr Rev 62:81–95. https://doi.org/10.1111/j.1753-4887.2004.tb00029.x
doi: 10.1111/j.1753-4887.2004.tb00029.x
pubmed: 15098855
Buta JG, Moline HE, Spaulding DW, Wang CY (1999) Extending storage life of fresh-cut apples using natural products and their derivatives. J Agric Food Chem 47:1–6. https://doi.org/10.1021/jf980712x
doi: 10.1021/jf980712x
pubmed: 10563838
Evans RT, Baker PJ, Coburn RA, Fischman SL, Genco RJ (1977) In vitro antiplaque effects of antiseptic phenols. J Periodontol 48:156–162. https://doi.org/10.1902/jop.1977.48.3.156
doi: 10.1902/jop.1977.48.3.156
pubmed: 264964
Leonard V, Frobisher M (1926) Clinical application of hexylresorcinol in urology with observations on the significance of surface tension in urinary antisepsis1. J Urol 15:1–10. https://doi.org/10.1016/S0022-5347(17)73434-9
doi: 10.1016/S0022-5347(17)73434-9
Kim J-Y, Seok H (2020) Role of 4-hexylresorcinol in the field of tissue engineering. Appl Sci 10:3385. https://doi.org/10.3390/app10103385
doi: 10.3390/app10103385
Won YK, Loy CJ, Randhawa M, Southall MD (2014) Clinical efficacy and safety of 4-hexyl-1,3-phenylenediol for improving skin hyperpigmentation. Arch Dermatol Res 306:455–465. https://doi.org/10.1007/s00403-014-1439-9
doi: 10.1007/s00403-014-1439-9
pubmed: 24402285
Shariff R, Du Y, Dutta M, Kumar ST, Thimmaiah S, Doraiswamy C, Kumari A, Kale V, Nair N, Zhang S et al (2022) Superior even skin tone and anti-ageing benefit of a combination of 4-hexylresorcinol and niacinamide. Int J Cosmet Sci 44:103–117. https://doi.org/10.1111/ics.12759
doi: 10.1111/ics.12759
pubmed: 34958693
pmcid: 9305876
Farris P, Zeichner J, Berson D (2016) Efficacy and tolerability of a skin brightening/anti-aging cosmeceutical containing retinol 0.5%, niacinamide, hexylresorcinol, and resveratrol. J Drugs Dermatol 15:863–868
pubmed: 27391637
National Center for Biotechnology Information. PubChem Compound Summary for CID 3610, Hexylresorcinol. https://pubchem.ncbi.nlm.nih.gov/compound/Hexylresorcinol . Accessed 10 Dec 2022
Frankos VH, Schmitt DF, Haws LC, McEvily AJ, Iyengar R, Miller SA, Munro IC, Clydesdale FM, Forbes AL, Sauer RM (1991) Generally recognized as safe (GRAS) evaluation of 4-hexylresorcinol for use as a processing aid for prevention of melanosis in shrimp. Regul Toxicol Pharmacol 14:202–212. https://doi.org/10.1016/0273-2300(91)90007-i
doi: 10.1016/0273-2300(91)90007-i
pubmed: 1792354
Matthews D, Adegoke O, Shephard A (2020) Bactericidal activity of hexylresorcinol lozenges against oropharyngeal organisms associated with acute sore throat. BMC Res Notes 13:99. https://doi.org/10.1186/s13104-020-04954-1
doi: 10.1186/s13104-020-04954-1
pubmed: 32093784
pmcid: 7041292
Kang Y-J, Oh J-H, Seok H, Jo Y-Y, Kim D-W, Garagiola U, Choi J-Y, Kim S-G (2020) 4-hexylresorcinol exhibits different characteristics to estrogen. Appl Sci 10:1737. https://doi.org/10.3390/app10051737
doi: 10.3390/app10051737
Fidalgo J, Deglesne PA, Arroya R, Ranneva E, Deprez P (2019) 4-hexylresorcinol a new molecule for cosmetic application. J Biomol Res Ther. https://doi.org/10.35248/2167-7956.19.8.170
doi: 10.35248/2167-7956.19.8.170
Kaur S, Kizoulis M, Fantasia J, Oddos T, Bigot N, Galera P, Tucker-Samaras S, Leyden JJ, Southall MD (2015) 4-Hexyl-1,3-phenylenediol, a nuclear factor-kappaB inhibitor, improves photodamaged skin and clinical signs of ageing in a double-blinded, randomized controlled trial. Br J Dermatol 173:218–226. https://doi.org/10.1111/bjd.13747
doi: 10.1111/bjd.13747
pubmed: 25752195